Danish pharmaceutical company Novo Nordisk boosted revenue by 21% in the third quarter to 71.3 billion Danish krone ($10.3 billion) in results released from company head office in Baegsvaerd on Wednesday. Net profits rose more than a fifth to 27.3 billion Danish krone, exceeding analysts’ expectations. Sales growth is now expected to come in at between 23% and 27%, with operating profits rising between 21% and 27%, excluding currency effects, the company said. The upper end of both ranges has been reduced slightly, while the lower has been raised. Novo Nordisk had slightly reduced its predicti…